Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo

Bone

Volumn 81, Issue , 2015, Pages 427-434

  Fujii, Toshiaki ^a   Ishikawa, Mizuho ^a   Kubo, Akiko ^a   Tanaka, Yoshitaka ^a  

^a SEIKAGAKU CORPORATION   (Japan)

Author keywords

Bone formation; Bone mineral density; Bone resorption; Cathepsin K; Inhibitor; Osteoporosis

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN B; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; DEOXYPYRIDINOLINE; N [1 [[[3 [(HEXAHYDRO 2 OXO 1H AZEPIN 3 YL)AMINO] 1 (1 METHYLETHYL) 2,3 DIOOPROPYL]AMINO]CARBONYL]CYCLOHEXYL] 2 FURANCARBOXAMIDE; OSTEOCALCIN; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDE; PEPTIDE; RECOMBINANT PROTEIN; SI-591;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM MOBILIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RAT; ANIMAL; ANIMAL FOOD; ANTAGONISTS AND INHIBITORS; BONE; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; FISCHER 344 RAT; HUMAN; LUMBAR VERTEBRA; METABOLISM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; RADIOGRAPHY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMAL FEED; ANIMALS; AZEPINES; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCIUM; CATHEPSIN K; COLLAGEN TYPE I; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PEPTIDES; PEPTIDOMIMETICS; RADIOGRAPHY; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 84940389954     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.08.016     Document Type: Article

References (46)

1. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377(9773):1276-1287. 10.1016/S0140-6736(10)62349-5.
2. Maclaughlin E.J., Sleeper R.B., McNatty D., Raehl C.L. Management of age-related osteoporosis and prevention of associated fractures. Ther. Clin. Risk Manag. 2006, 2(3):281-295. (PMID:18360603).
3. Sweet M.G., Sweet J.M., Jeremiah M.P., Galazka S.S. Diagnosis and treatment of osteoporosis. Am. Fam. Physician 2009, 79(3):193-200. (PMID:19202966).
4. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49(1):50-55. 10.1016/j.bone.2010.08.008.
5. Suresh E., Pazianas M., Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014, 53(1):19-31. 10.1093/rheumatology/ket236.
6. Gedmintas L., Solomon D.H., Kim S.C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J. Bone Miner. Res. 2013, 28(8):1729-1737. 10.1002/jbmr.1893.
7. Hassager C., Risteli J., Risteli L., Jensen S.B., Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 1992, 7(11):1307-1311. 10.1002/jbmr.5650071110.
8. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem. 1993, 39(4):635-640. (PMID:8472358).
9. Kumar S., Dare L., Vasko-Moser J.A., James I.E., Blake S.M., Rickard D.J., et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007, 40(1):122-131. 10.1016/j.bone.2006.07.015.
10. Kim M.K., Kim H.D., Park J.H., Lim J.I., Yang J.S., Kwak W.Y., et al. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo -piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J. Pharmacol. Exp. Ther. 2006, 318(2):555-562. 10.1124/jpet.106.102798.
11. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14(10):1654-1663. 10.1359/jbmr.1999.14.10.1654.
12. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(23):13453-13458. 10.1073/pnas.95.23.13453.
13. Delaissé J.M., Andersen T.L., Engsig M.T., Henriksen K., Troen T., Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 2003, 61(6):504-513. 10.1002/jemt.10374.
14. Toral-López J., Gonzalez-Huerta L.M., Sosa B., Orozco S., González H.P., Cuevas-Covarrubias S.A. Familial pycnodysostosis: identification of a novel mutation in the CTSK gene (cathepsin K). J. Investig. Med. 2011, 59(2):277-280. 10.231/JIM.0b013e318202a9db.
15. Schilling A.F., Mülhausen C., Lehmann W., Santer R., Schinke T., Rueger J.M., et al. High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos. Int. 2007, 18(5):659-669. 10.1007/s00198-006-0311-y.
16. Adami S., Supronik J., Hala T., Brown J.P., Garnero P., Haemmerle S., et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis (abstract). J. Bone Miner. Res. 2006, 21(Suppl. 1):S24. 10.1002/jbmr.5650211402.
17. Peroni A., Zini A., Braga V., Colato C., Adami S., Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J. Am. Acad. Dermatol. 2008, 59(1):125-129. 10.1016/j.jaad.2008.03.009.
18. Rünger T.M., Adami S., Benhamou C.L., Czerwiński E., Farrerons J., Kendler D.L., et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J. Am. Acad. Dermatol. 2012, 66(3):e89-e96. 10.1016/j.jaad.2010.11.033.
19. Falgueyret J.P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off target cathepsins and reduced functional selectivity. J. Med. Chem. 2005, 48(24):7535-7543. 10.1021/jm0504961.
20. Desmarais S., Black W.C., Oballa R., Lamontagne S., Riendeau D., Tawa P., et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol. Pharmacol. 2008, 73(1):147-156. 10.1124/mol.107.039511.
21. Brömme D., Okamoto K., Wang B.B., Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. 1996, 271(4):2126-2132. 10.1074/jbc.271.4.2126.
22. Brömme D., Bescherer K., Kirschke H., Fittkau S. Enzyme-substrate interactions in the hydrolysis of peptides by cathepsin B and H from rat liver. Biochem. J. 1987, 245(2):381-385. (PMID:3663163).
23. McDonald J.K., Kadkhodayan S. Cathepsin L a latent proteinase in guinea pig sperm. Biochem. Biophys. Res. Commun. 1988, 151(2):827-835. (PMID:3348813).
24. Kirshke H., Wiederanders B., Brömme D., Rinne A., Cathepsin S. from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J. 1989, 264(2):467-473. (PMID:2690828).
25. Susa M., Luong-Nguyen N.H., Cappellen D., Zamurovic N., Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J. Transl. Med. 2004, 2(1):6. 10.1186/1479-5876-2-6.
26. Ito M., Amizuka N., Nakajima T., Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999, 25(4):447-452. 10.1016/S8756-3282(99)00197-0.
27. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N. Y. Acad. Sci. 2007, 1117:209-257. 10.1196/annals.1402.089.
28. Tada S., Tsutsumi K., Ishihara H., Suzuki K., Gohda K., Teno N. Species differences between human and rat in the substrate specificity of cathepsin K. J. Biochem. 2008, 144(4):499-506. 10.1093/jb/mvn093.
29. Wolinsky I., Guggenheim K. Effect of low calcium diet on bone and calcium metabolism in rats and mice-a differential species response. Comp. Biochem. Physiol. A Comp. Physiol. 1974, 49(1A):183-195. (PMID:4153653).
30. Ornoy A., Wolinsky I., Guggenheim K. Structure of long bones of rats and mice fed a low calcium diet. Calcif. Tissue Res. 1974, 15(1):71-76. (PMID:4843783).
31. Turner A.S. Animal models of osteoporosis-necessity and limitations. Eur. Cell. Mater. 2001, 22(1):66-81. (PMID:14562261).
32. Mundy G.R., Guise T.A. Hormonal control of calcium homeostasis. Clin. Chem. 1999, 45(8 Pt 2):1347-1352. (PMID:10430817).
33. Thompson D.D., Simmons H.A., Pirie C.M., Ke H.Z. FDA Guidelines and animal models for osteoporosis. Bone 1995, 17(4 Suppl.):125S-133S. (PMID:8579908).
34. Tamura Y., Miyakoshi N., Itoi E., Abe T., Kudo T., Tsuchida T., et al. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J. Bone Miner. Res. 2001, 16(3):541-549. 10.1359/jbmr.2001.16.3.541.
35. Cheng Z., Yao W., Zimmermann E.A., Busse C., Ritchie R.O., Lane N.E. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J. Bone Miner. Res. 2009, 24(2):209-220. 10.1359/jbmr.81005.
36. Gasser J.A., Ingold P., Venturiere A., Shen V., Green J.R. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J. Bone Miner. Res. 2008, 23(4):544-551. 10.1359/jbmr.071207.
37. Swaminathan R. Biochemical markers of bone turnover. Clin. Chim. Acta 2001, 313(1-2):95-105. 10.1016/S0009-8981(01)00656-8.
38. Saag K., Lindsay R., Kriegman A., Beamer E., Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007, 40(5):1238-1243. 10.1016/j.bone.2007.01.016.
39. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002, 346(9):653-661. 10.1056/NEJMoa011807.
40. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. (Br.) 2007, 89(3):349-353. 10.1302/0301-620X.89B3.18146.
41. Whyte M.P. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J. Bone Miner. Res. 2009, 24(6):1132-1134. 10.1359/jbmr.081253.
42. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 2008, 93(6):2149-2157. 10.1210/jc.2007-2814.
43. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006, 354(8):821-831. 10.1056/NEJMoa044459.
44. Smith M.R., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet Jan 7 2012, 379(9810):39-46. 10.1016/S0140-6736(11)61226-9.
45. Barasch A., Cunha-Cruz J., Curro F.A., Hujoel P., Sung A.H., Vena D., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J. Dent. Res. Apr 2011, 90(4):439-444. 10.1177/0022034510397196.
46. Mavrokokki T., Cheng A., Stein B., Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. Mar 2007, 65(3):415-423. 10.1016/j.joms.2006.10.061.